Navigation Links
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
Date:9/30/2010

n compared with bare metal stents.

About Cordis Corporation

For more than 50 years, Cordis Corporation, a Johnson & Johnson company, has been a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease.

*Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a trademark of Wyeth Pharmaceuticals.

**The third party trademarks used herein are trademarks of their respective owners.


'/>"/>
SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
2. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
5. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
6. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
9. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
10. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
11. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
(Date:10/20/2014)... Norgine B.V. today announced that ... bowel preparation, NER1006, presented at the 79 th ... (ACG), Philadelphia, PA , has met ... co-primary endpoint of cleansing success. The study demonstrated high ... in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... FRANKFURT , Deutschland, October 19, 2014 /PRNewswire/ ... echten CRT-Fallstudien gefragt. Das Problem dabei ... ihre Informationen mit der Kompetenz zu teilen. ... zusammenzustellen, und deshalb freuen wir uns umso mehr, ... Pharmafirmen gebeten, ihre Gepflogenheiten bei Kühlketten aufzuschreiben - ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... Arthritis Foundation,the leading health organization addressing the needs ... that Amgen and Wyeth,Pharmaceuticals, co-marketers of Enbrel (R) ... 2008 Arthritis Walk (R)., "The Arthritis Foundation ... funds to prevent, control and cure arthritis, the,nation,s ...
... in, Achieving Red Blood Cell Transfusion Independence, Hematologic Improvement ... ... the 49th American Society of Hematology (ASH) Meeting, ATLANTA, ... interim data from a Phase 2 clinical trial,evaluating three alternative ...
Cached Medicine Technology:Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 2Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 3Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 4MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 2MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 3MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 4MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 5MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 6
(Date:10/20/2014)... It’s hard to imagine what it’s like to ... around the world, it’s a reality. And while new shoes ... forced to walk barefoot on rocky terrain or sewage-lined streets ... their friends. , Buckner International's Shoes for Orphan ... in October to encourage support for Air1 and while also ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
(Date:10/19/2014)... 20, 2014 Having been working in the ... knowledge of customer needs. According to James, one of the ... dazzling sequins, or with high-low skirts that add beauty to ... demand. Recently, LunaDress has unveiled its new selection of 2014 ... the company’s brand new items are available in over 20 ...
(Date:10/19/2014)... a professional company of women’s dresses and related accessories, ... dresses . All the company’s old and new client ... up to 66 percent off. , SweetDressy.com is ... Its dress specialists are striving to make more trendy ... world. All the company’s items are unique, graceful and ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... earlier U.S. study had different conclusion , THURSDAY, April ... being treated for erectile dysfunction finds an association between ... of the male hormone testosterone. , The study "sends ... director of sexual medicine at Alvarado Hospital in San ...
... plateaus, says CDC report , THURSDAY, April 15 (HealthDay ... food-related illnesses caused by several common bacteria, including the most ... a pathogen most often acquired from oysters which can cause ... rates of Salmonella infection have remained flat in recent years. ...
... conducted by a collaborative team led by researchers from the ... into the clinical outcome for some patients with a particularly ... a framework for development of targeted drug treatments. The ... in the journal Cancer Cell, used epigenomics to ...
... baby boomers will benefit from Social Security and Medicare at ... government-run programs will pay out more than they collect in ... from the University of California, Berkeley, concludes that younger Americans ... actually getting the better deal when the value of public ...
... ... Solution Enhances Tracking and Management of Items, Assets, and Containers, , ... (PRWEB) April 15, 2010 -- ... Frequency Identification (RFID) solutions, today announced that they are partnering to offer the industry,s ...
... ... to announce that Maureen Hanrahan has joined the company as a senior consultant specializing ... Medicaid and SCHIP. , ... (PRWEB) April 15, 2010 -- ArpegioHealth is pleased to announce that ...
Cached Medicine News:Health News:Do Statins Lower Male Sex Drive? 2Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 2Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 3Health News:USC researchers discover new molecular subtype of brain cancer 2Health News:For post-boomers, public education worth more than Social Security and Medicare 2Health News:For post-boomers, public education worth more than Social Security and Medicare 3Health News:Savi and ODIN to Deliver Industry's Most Comprehensive RFID Software Platform 2Health News:Savi and ODIN to Deliver Industry's Most Comprehensive RFID Software Platform 3Health News:Hanrahan Joins ArpegioHealth Consulting Firm 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... immunosorbent assay method for the semi-quantitative ... myeloperoxidase in human serum. The results ... used as an aid in the ... conditions associated with elevated anti-neutrophil cytoplasmic ...
... Ang II is a helpful ... effect and efficiency of a ... enzyme inhibitors (ACE Inhibitors) or ... well as for the efficiency ...
Medicine Products: